Lonza announced its plans to invest in establishing drug product manufacturing capabilities at its site in Guangzhou, China. The new investment will fund the installation of an aseptic drug product fill and finish production line at the 17,000 m2 state-of-the-art cGMP mammalian facility. This will significantly expand the site’s capabilities, supporting global and domestic customers with supply for clinical trials and commercial batches in China. It will support the filling of liquid and lyophilized products. The installation is expected to be completed in 2022 and will create more than 150 new positions at the site.
The Guangzhou (CN) facility began operations in Q2 2021 and expects to deliver its first cGMP batch later this year. The introduction of drug product manufacturing will provide a combined drug substance and drug product manufacturing service offering for customers, which is a part of Lonza’s strategy to provide integrated end-to-end solutions to customers.
In addition, Lonza plans to expand the footprint of its global Drug Product Services hub in Basel (CH). Lonza’s Drug Product Services laboratories are a Center of Excellence, supporting drug product capabilities across the company’s global network by providing formulation development and process development.
For more information about the manufacturing capabilities at the Guangzhou (CN) site, please visit: https://pharma.lonza.com/about/locations/guangzhou-china